Olaris Presents "Plasma-based metabolic profiling in metastatic gastrointestinal stromal tumors (GIST)" at AACR 2021
The presentation, led by Olaris Metabolite Scientist Dr. Chandrashekhar Honrao, highlights the use of Olaris’ BoR platform to identify metabolic signatures correlated with overall survival and to predict response or resistance to treatment in patients with advanced GIST. “Targeted treatments have revolutionized cancer care, especially for GIST. However, due to patient heterogeneity it remains challenging to know who will benefit from one therapy over another. This study is particularly exciting as we were able to demonstrate and validate in an independent set of patient samples that metabolite biomarkers either before treatment or during treatment can identify patients with favorable clinical outcomes” said Dr. Elizabeth O’Day, CEO and Founder of Olaris.
Olaris publishes in special Non-Uniform Sampling issue of Magnetic Resonance in Chemistry
Dr. Elizabeth O'Day and Leslie Hoyt's paper on discusses the opportunity for NUS NMR metabolite in-vitro diagnostics- key tools that can accelerate the goals of precision medicine.
The ease of sample preparation, quantification of metabolite levels for overlapping peaks often found in patient samples, and reproducibility afforded by NMR can be used to develop metabolite based diagnostics with NUS. This may serve to reduce the long acquisition time associated with NMR.
Olaris presents NMR-based Metabolomics Data at ENC
Olaris' will be presenting a poster and giving a talk at the ENC! The Experimental NMR Conference features innovative research in NMR spectroscopy and Olaris is very excited to share our recent studies on the power of NUS 13C 1H HSQC NMR. See the poster below.
Olaris announces findings from exploratory analysis of biomarkers that predict patient responsiveness to Trastuzumab therapy
Olaris’ metabolite profiling platform and machine learning algorithms have the potential to accurately indicate whether HER2-positive metastatic breast cancer patients will respond to trastuzumab therapy.
Olaris presents poster at the San Antonio Breast Cancer Symposium
Olaris is thrilled to present at the SABCS! We are excited to learn from the world's top breast cancer oncologists and share the results of our recent study, "Pretreatment serum metabolome predicts PFS in first-line trastuzumab-treated metastatic breast cancer." Learn more about our findings here.
Olaris Metabolite Scientist, Dr. Bo Zhang, published in Analytical Chemistry
"Accurate and Efficient Determination of Unknown Metabolites in Metabolomics by NMR-Based Molecular Motif Identification" discusses the new SUMMIT method to identify chemical classes of metabolites, a critical tool in understanding patient health and disease. Read the paper here!
Olaris Metabolite Scientist, Dr. Chandra Honrao, published in Nature Research
We are so proud of Dr. Honrao for his work in helping to discover a new antibiotic for Gram-negative pathogens, a notoriously difficult pathogen to target. In fact, the last development in antibiotics for Gram-negative bacteria was in the 1960s. The exciting discovery has the potential to be developed into new therapeutics. Read the paper here!
Olaris CEO publishes "Cytidine monophosphate N-acetylneuraminic acid synthetase enhances invasion of human triple-negative breast cancer cells"
Cancer cells have altered bioenergetics, which contributes to their ability to proliferate, survive in unusual microenvironments, and invade other tissues. Changes in glucose metabolism can have pleomorphic effects on tumor cells. To investigate potential mechanisms responsible for the increased malignancy associated with altered glucose metabolism, we used Olaris technology to identify glucose metabolites differentially produced in a highly malignant human triple-negative breast cancer (TNBC) cell line (BPLER) and a less malignant isogenic TNBC cell line (HMLER).